Myostatin and muscle atrophy during chronic kidney disease
Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the my...
Uložené v:
| Vydané v: | Nephrology, dialysis, transplantation Ročník 36; číslo 11; s. 1986 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
09.11.2021
|
| Predmet: | |
| ISSN: | 1460-2385, 1460-2385 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-β superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin-proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD. |
|---|---|
| AbstractList | Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-β superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin-proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD. Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-β superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin-proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD.Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major signalling pathways control protein synthesis, the insulin-like growth factor-1/Akt (IGF-1/Akt) pathway, acting as a positive regulator, and the myostatin (Mstn) pathway, acting as a negative regulator. Mstn, also known as the growth development factor-8 (GDF-8), is a member of the transforming growth factor-β superfamily, which is secreted by mature muscle cells. Mstn inhibits satellite muscle cell proliferation and differentiation and induces a proteolytic phenotype of muscle cells by activating the ubiquitin-proteasome system. Recent advances have been made in the comprehension of the Mstn pathway disturbance and its role in muscle wasting during CKD. Most studies report higher Mstn concentrations in CKD and dialysis patients than in healthy subjects. Several factors increase Mstn production in uraemic conditions: low physical activity, chronic or acute inflammation and oxidative stress, uraemic toxins, angiotensin II, metabolic acidosis and glucocorticoids. Mstn seems to be only scarcely removed during haemodialysis or peritoneal dialysis, maybe because of its large molecule size in plasma where it is linked to its prodomain. In dialysis patients, Mstn has been proposed as a biomarker of muscle mass, muscle strength or physical performances, but more studies are needed in this field. This review outlines the interconnection between Mstn activation, muscle dysfunction and CKD. We discuss mechanisms of action and efficacy of pharmacological Mstn pathway inhibition that represents a promising treatment approach of striated muscle dysfunction. Many approaches and molecules are in development but until now, no study has proved a benefit in CKD. |
| Author | Bataille, Stanislas Koppe, Laetitia Chauveau, Philippe Fouque, Denis Aparicio, Michel |
| Author_xml | – sequence: 1 givenname: Stanislas orcidid: 0000-0001-8344-1300 surname: Bataille fullname: Bataille, Stanislas organization: Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France – sequence: 2 givenname: Philippe surname: Chauveau fullname: Chauveau, Philippe organization: Aurad-Aquitaine, Gradignan, France – sequence: 3 givenname: Denis surname: Fouque fullname: Fouque, Denis organization: Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, Villeurbanne, France – sequence: 4 givenname: Michel surname: Aparicio fullname: Aparicio, Michel organization: Aurad-Aquitaine, Gradignan, France – sequence: 5 givenname: Laetitia surname: Koppe fullname: Koppe, Laetitia organization: Univ. Lyon, CarMeN lab, INSA-Lyon, INSERM U1060, INRA, Université Claude Bernard Lyon 1, Villeurbanne, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32974666$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNjztPwzAYRS1URB8wsaOMLKF-O2ZDFS-piKV75NqfW0PilNgZ8u8pokhM9-rq6Epnjiaxi4DQNcF3BGu2jC4vd94YQvUZmhEucUlZJSb_-hTNU_rAGGuq1AWaMqoVl1LO0P3b2KVscoiFia5oh2QbKEzuu8N-LNzQh7gr7L7vYrDFZ3ARjmtIYBJconNvmgRXp1ygzdPjZvVSrt-fX1cP69JyynIpnFLGeMmoJ8JqvyWVd4IBUOWYZtwRACEd5Y5KwVVljWZK-koo4zh4ukC3v7eHvvsaIOW6DclC05gI3ZBqyn9MSIXZEb05ocO2BVcf-tCafqz_dOk3X6dZCg |
| CitedBy_id | crossref_primary_10_1002_fsn3_70624 crossref_primary_10_1093_ndt_gfad123 crossref_primary_10_3390_toxins17040159 crossref_primary_10_1007_s00223_020_00782_4 crossref_primary_10_3390_biomedicines11072076 crossref_primary_10_1007_s13668_025_00637_0 crossref_primary_10_1016_j_nefro_2025_501337 crossref_primary_10_1007_s11255_022_03393_0 crossref_primary_10_1186_s13102_024_00825_5 crossref_primary_10_1002_jcsm_13066 crossref_primary_10_1016_j_exger_2024_112571 crossref_primary_10_3390_ijms24054462 crossref_primary_10_3390_healthcare13131621 crossref_primary_10_1186_s12882_025_04057_8 crossref_primary_10_3389_fphar_2022_859723 crossref_primary_10_3390_medicina61030449 crossref_primary_10_3390_nu13051538 crossref_primary_10_1159_000539489 crossref_primary_10_3390_ijms23116047 crossref_primary_10_1016_j_jss_2024_07_054 crossref_primary_10_3390_ijms26073098 crossref_primary_10_1007_s10142_025_01698_8 crossref_primary_10_1016_j_bcp_2022_115407 crossref_primary_10_3389_fnut_2023_1223975 crossref_primary_10_1053_j_jrn_2025_01_005 crossref_primary_10_3389_fendo_2023_1146868 crossref_primary_10_3390_diseases12120328 crossref_primary_10_1002_jcp_31418 crossref_primary_10_1007_s42000_024_00586_3 crossref_primary_10_1002_jcsm_12839 crossref_primary_10_1002_rco2_87 crossref_primary_10_1080_01913123_2024_2446242 crossref_primary_10_1038_s41430_022_01227_x crossref_primary_10_3390_nu16152480 crossref_primary_10_3390_cells14161228 crossref_primary_10_3390_nu17030404 crossref_primary_10_3390_ijms222212112 crossref_primary_10_1089_crispr_2022_0009 crossref_primary_10_3390_nu17030488 crossref_primary_10_3389_fphar_2024_1418485 crossref_primary_10_1016_j_jep_2024_118917 crossref_primary_10_2147_DMSO_S410834 crossref_primary_10_3390_ijerph19010465 crossref_primary_10_3389_fmed_2025_1546988 crossref_primary_10_1016_j_jprot_2024_105283 crossref_primary_10_3389_fimmu_2021_587146 crossref_primary_10_3390_ijms25105117 crossref_primary_10_1016_j_biopha_2024_116556 crossref_primary_10_1159_000538533 crossref_primary_10_3389_fendo_2022_811751 crossref_primary_10_1139_apnm_2021_0521 crossref_primary_10_1007_s11914_022_00751_w crossref_primary_10_1093_ndt_gfae193 crossref_primary_10_1016_j_numecd_2022_02_005 crossref_primary_10_3389_fnut_2021_683393 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. |
| Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/ndt/gfaa129 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2385 |
| ExternalDocumentID | 32974666 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 29M 2WC 4.4 482 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAHTB AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SDH TCURE TEORI TJX TR2 W8F WH7 WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c423t-5d77aaf632f15c9fb18fd53ee27d3934d1ee56d24d265478ca9376f857ad4ef2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 65 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000728382400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2385 |
| IngestDate | Mon Sep 29 06:23:45 EDT 2025 Mon Jul 21 05:38:21 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | wasting chronic kidney disease myostatin sarcopenia |
| Language | English |
| License | The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c423t-5d77aaf632f15c9fb18fd53ee27d3934d1ee56d24d265478ca9376f857ad4ef2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-8344-1300 |
| PMID | 32974666 |
| PQID | 2446661803 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2446661803 pubmed_primary_32974666 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-09 |
| PublicationDateYYYYMMDD | 2021-11-09 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-09 day: 09 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Nephrology, dialysis, transplantation |
| PublicationTitleAlternate | Nephrol Dial Transplant |
| PublicationYear | 2021 |
| SSID | ssj0009277 |
| Score | 2.5779958 |
| SecondaryResourceType | review_article |
| Snippet | Chronic kidney disease (CKD) patients often exhibit a low muscle mass and strength, leading to physical impairment and an increased mortality. Two major... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1986 |
| SubjectTerms | Humans Muscle, Skeletal Muscular Atrophy - etiology Myostatin Renal Dialysis Renal Insufficiency, Chronic - therapy Uremic Toxins |
| Title | Myostatin and muscle atrophy during chronic kidney disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32974666 https://www.proquest.com/docview/2446661803 |
| Volume | 36 |
| WOSCitedRecordID | wos000728382400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbyGdpNmk3gREYsHW3oo0tuSzUOKmK1uK_jvnexu6U0EL3vY3cAyOzP5Mo9vELrhTMQy3Jwo7jWJjOBE5mCPwiSegzmlpiL1eXkWw6GcTNSoCbiVTVnl0idWjtoWJsbIOzQmHtNEdtnd7IPEqVExu9qM0FhHLQZQJmq1mKzYwhWtJi-CM-gS2Jp4058Hh_hOsPPOq9c6-Q1bVntMf_e_X7eHdhp0ie9rddhHay4coK1Bkz8_RLeD7yK2EE0D1sHi90UJr-EYDgdp47plEZuaLxe_TW1wcLdO4Ryhcf9x_PBEmukJxABEmhNuhdDap4z6hBvl80R6y5lzVFimWM8mzvHU0p6lcQCxNBqQSuolF9r2nKfHaCMUwZ0ibCWskp6luYvk-wIQpQOkwb2Smgsl2uh6KZQMlDNmHHRwxaLMVmJpo5NastmsZtHIGIWjDDw9-8Pqc7RNYy1JDOeqC9TyYJruEm2ar_m0_Lyq_jpch6PBD5aXuCY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Myostatin+and+muscle+atrophy+during+chronic+kidney+disease&rft.jtitle=Nephrology%2C+dialysis%2C+transplantation&rft.au=Bataille%2C+Stanislas&rft.au=Chauveau%2C+Philippe&rft.au=Fouque%2C+Denis&rft.au=Aparicio%2C+Michel&rft.date=2021-11-09&rft.eissn=1460-2385&rft.volume=36&rft.issue=11&rft.spage=1986&rft_id=info:doi/10.1093%2Fndt%2Fgfaa129&rft_id=info%3Apmid%2F32974666&rft_id=info%3Apmid%2F32974666&rft.externalDocID=32974666 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2385&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2385&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2385&client=summon |